Modulation of autophagy: A phase II study of vorinostat (VOR) plus hydroxychloroquine (HCQ) vs regorafenib (RGF) in chemo-refractory metastatic colorectal cancer (mCRC).

被引：6
|
作者：
Arora, Sukeshi Patel
Tenner, Laura LaNiel
Sarantopoulos, John
Morris, Jay Larry
Longoria, Lisa
Liu, Qianqian
Michalek, Joel
Mahalingam, Devalingam
机构：
[1] UT Hlth San Antonio Canc Ctr, San Antonio, TX USA
[2] Univ Texas Hlth San Antonio, Mays Canc Ctr, Inst Drug Dev, San Antonio, TX USA
[3] Northwestern Univ, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.3551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3551
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)
    Sukeshi Patel Arora
    Laura Tenner
    John Sarantopoulos
    Jay Morris
    Qianqian Liu
    Jenny A. Mendez
    Tyler Curiel
    Joel Michalek
    Devalingam Mahalingam
    British Journal of Cancer, 2022, 127 : 1153 - 1161
  • [2] Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)
    Arora, Sukeshi Patel
    Tenner, Laura
    Sarantopoulos, John
    Morris, Jay
    Liu, Qianqian
    Mendez, Jenny A.
    Curiel, Tyler
    Michalek, Joel
    Mahalingam, Devalingam
    BRITISH JOURNAL OF CANCER, 2022, 127 (06) : 1153 - 1161
  • [3] Effect of vorinostat (VOR) and hydroxychloroquine (HCQ) on immunity and autophagy in metastatic colorectal cancer (mCRC).
    Patel, Sukeshi R.
    Hurez, Vincent
    Nawrocki, Steffan T.
    Goros, Martin
    Michalek, Joel
    Sarantopoulos, John
    Curiel, Tyler J.
    Mahalingam, Devalingam
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [4] Phase II study of ruxolitinib with regorafenib for relapsed/refractory (r/r) metastatic colorectal cancer (mCRC).
    Fogelman, David R.
    Kochenderfer, Mark D.
    Saylors, Gene Brian
    Braiteh, Fadi S.
    Nemunaitis, John J.
    Cohn, Allen Lee
    O'Neill, Peter
    Zhou, Li
    Switzky, Julie C.
    Assad, Albert
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] NSABP FC-10: Phase IB study of pembrolizumab in combination with premetrexed plus oaliplatin in patients (pts) with chemo-refractory metastatic colorectal cancer (mCRC)
    Lee, James J.
    Yothers, Greg
    George, Thomas J.
    Krauss, John C.
    Maalouf, Bassam Nabih
    Parekh, Hiral D.
    Krishnamurthy, Anuradha
    Vehec, Kelly R.
    Wolmark, Norman
    Allegra, Carmen Joseph
    Jacobs, Samuel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [6] FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial
    Bellio, Helene
    Roussot, Nicolas
    Bertaut, Aurelie
    Hervieu, Alice
    Zanetta, Sylvie
    Tharin, Zoe
    Vincent, Julie
    Bengrine, Leila
    Hennequin, Audrey
    Guion, Jean-Florian
    Boudrant, Axelle
    Collot, Thomas
    Ghiringhelli, Francois
    Fumet, Jean-David
    FUTURE ONCOLOGY, 2025, 21 (06) : 699 - 706
  • [7] Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
    Hsieh, M-C.
    Chen, H-P.
    Rau, K-M.
    Lin, S-E.
    Liu, K-W.
    Chiu, C-C.
    Chen, C-I.
    Song, L-C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1515 - S1515
  • [8] Regorafenib dose optimization study (ReDOS): A phase II randomized study of lower starting dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (mCRC)
    Bekaii-Saab, Tanios S.
    Ou, Fang-Shu
    Ciombor, Kristen Keon
    Farhat, Mohamed I.
    Kirshner, Jeffrey J.
    Knost, James A.
    Anderson, Daniel M.
    Soori, Gamini S.
    Boland, Patrick Mckay
    Wender, Donald B.
    Desnoyers, Rodwige J.
    Sargent, Daniel J.
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).
    Altomare, I.
    Russell, K. B.
    Uronis, H. E.
    Morse, M.
    Hsu, S. D.
    Zafar, Y.
    Bendell, J. C.
    Starodub, A.
    Honeycutt, W.
    Hurwitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Phase II study of modulation of sorafenib (SOR)-induced autophagy using hydroxychloroquine (HCQ) in advanced hepatocellular cancer (HCC).
    Arora, Sukeshi Patel
    Moseley, Jennifer L.
    Arellano, Luisa Marie
    Salazar, Mary
    Altermatt, Brittany
    Fuentes, Lorena
    Pham, Vincent Truong
    Huang, Gang
    Sun, LuZhe
    Michalek, Joel
    Mahalingam, Devalingam
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
12345